![]() |
Name |
Calvasterol A
|
Molecular Formula | C28H38O3 | |
IUPAC Name* |
(10R,13R,14S,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-14-hydroxy-10,13-dimethyl-1,2,12,15,16,17-hexahydrocyclopenta[a]phenanthrene-3,6-dione
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC(=O)C4=CC(=O)CC[C@]34C)C)O
|
|
InChI |
InChI=1S/C28H38O3/c1-17(2)18(3)7-8-19(4)21-11-14-28(31)23-16-25(30)24-15-20(29)9-12-26(24,5)22(23)10-13-27(21,28)6/h7-8,10,15-19,21,31H,9,11-14H2,1-6H3/b8-7+/t18-,19+,21+,26+,27+,28+/m0/s1
|
|
InChIKey |
JABICPUHELULCU-OCOXMEBRSA-N
|
|
Synonyms |
Calvasterol A; 162857-85-4
|
|
CAS | NA | |
PubChem CID | 10251684 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 422.6 | ALogp: | 4.5 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 54.4 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.576 |
Caco-2 Permeability: | -4.747 | MDCK Permeability: | 0.00002850 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.044 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.737 | Plasma Protein Binding (PPB): | 87.41% |
Volume Distribution (VD): | 0.95 | Fu: | 3.02% |
CYP1A2-inhibitor: | 0.024 | CYP1A2-substrate: | 0.253 |
CYP2C19-inhibitor: | 0.06 | CYP2C19-substrate: | 0.694 |
CYP2C9-inhibitor: | 0.244 | CYP2C9-substrate: | 0.02 |
CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.004 |
CYP3A4-inhibitor: | 0.874 | CYP3A4-substrate: | 0.948 |
Clearance (CL): | 3.548 | Half-life (T1/2): | 0.177 |
hERG Blockers: | 0.182 | Human Hepatotoxicity (H-HT): | 0.372 |
Drug-inuced Liver Injury (DILI): | 0.118 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.917 | Maximum Recommended Daily Dose: | 0.956 |
Skin Sensitization: | 0.551 | Carcinogencity: | 0.722 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.987 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004905 | ![]() |
0.663 | D0G8OC | ![]() |
0.323 | ||
ENC002985 | ![]() |
0.650 | D06JPB | ![]() |
0.323 | ||
ENC002188 | ![]() |
0.650 | D0G5CF | ![]() |
0.317 | ||
ENC002480 | ![]() |
0.527 | D04GJN | ![]() |
0.310 | ||
ENC002984 | ![]() |
0.523 | D02CNR | ![]() |
0.309 | ||
ENC004615 | ![]() |
0.496 | D0I2SD | ![]() |
0.267 | ||
ENC004906 | ![]() |
0.482 | D0G8BV | ![]() |
0.265 | ||
ENC003120 | ![]() |
0.482 | D04ATM | ![]() |
0.264 | ||
ENC004737 | ![]() |
0.477 | D0Z1XD | ![]() |
0.261 | ||
ENC004022 | ![]() |
0.477 | D0IX6I | ![]() |
0.260 |